Breast cancer (BC) involves complex signaling networks characterized by extensive cross-
communication and feedback loops between and within multiple signaling cascades. Many …

Breast cancer is the most prevalent cancer and the leading cause of cancer-related death
among women worldwide. Type 2 diabetes–associated metabolic traits such as …

Due to the strong association between diabetes and cancer incidents, several anti-diabetic
drugs, including metformin, have been examined for their anticancer activity. Metformin is a …

FLT3 tyrosine kinase inhibitor (TKI) therapy evolved into a standard therapy in FLT3-mutated
AML. TKI resistance, however, develops frequently with poor outcomes. We analyzed …

m6A (N 6-methyladenosine) is the most common type of RNA methylation modification,
mainly occurring on mRNA. Whether m6A-modified circular RNAs (circRNAs) are involved in …

Aims Despite metformin being used as first-line pharmacological therapy for type 2 diabetes,
its underlying mechanisms remain unclear. We aimed to determine whether metformin …

Human epidermal growth factor 2 (HER2)+ breast cancer is considered the most dangerous
type of breast cancers. Herein, we used bioinformatics methods to identify potential key …

Increasing evidence highlights approaches targeting metabolism as potential adjuvants to
cancer therapy. Sodium-glucose transport protein 2 (SGLT2) inhibitors are the newest class …

The HER2-positive breast cancer subtype (HER2+-BC) displays a particularly aggressive
behavior. Anti-HER2 therapies have significantly improved the survival of patients with …

Background New biomarkers are needed to identify different clinical outcomes for HER2+
breast cancer (BC). Methods Differential genes of HER2+ BC were screened based on …